Vertex Pharmaceuticals Gets a Huge FDA Approval Which Could Send the Stock Skyrocketing
Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...
Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off
Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.
Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst
Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...
AstraZeneca upgraded by UBS to buy on growth potential
UBS has upgraded AstraZeneca (NASDAQ:AZN) to buy from neutral, stating it believes the company's in-market growth potential has been underestimated. The investment bank said its forecasts for the ...
pharmaphorum20h
Santhera's DMD drug poised for wider rollout in Germany
The Swiss biopharma company said the deal with the German National Association of Statutory Health Insurance Funds (GKV-SV) ...